Page 552«..1020..551552553554..560570..»

ATMPS and Assurea team up to ensure audit readiness for cell and gene therapy innovators – BioPharma-Reporter.com

Posted: January 5, 2022 at 2:02 am

ATMPS Hataali is a secure data sharing platform, specially designed as a scalable system for advanced therapies. The developer describes it as a vein to vein, blockchain based, cell orchestration platform, providing full chain of custody, identity, and condition information.

It allows multiple stakeholders - hospitals, manufacturers, couriers - to communicate and coordinate their activities in real time, thereby increasing efficiency, ensuring patient safety and regulatory compliance, Raja Sharif, CEO of ATMPS, told us in May last year.

Assurea, which specializes in navigating the complex regulatory pathway for advanced therapies, has already begun working with ATMPS on a number of collaborative projects, including one for a UK based phase I biotech focused on CAR-T.

The partners want to target pre-clinical companies heading into the IND stage, as well as well providing data rescue systems for therapies already undergoing trials. The latter issue, they said, is a growing area of concern as many biotech companies realize that, as key regulatory touchpoints approach, they dont have a robust enough platform to stand up to intense regulatory scrutiny.

This collaboration enables biotechs and innovators to have regulatory-ready, decentralized data records that have integrity built-in by design.

"Its a completely different way of tackling compliance and provides investors with increased confidence in the results gained and initial valuations.

"Looking further ahead, it also means they can have confidence that trials are progressing as they should, with data available in near real-time and, crucially, have the ability to scale quickly, said Sharif.

Using this blockchain system means even the smallest companies can now operate a continual state of audit readiness, rather than scrambling for records as an audit or inspection approaches, said the partners.

This joint approach will lead to higher valuations, increased security and potentially better returns for biotechs as the immutable records will back up every claim and data point with an irrefutable record, providing greater trust for an industry that has seen a number of prominent data scandals in the last few years, they continued.

This collaboration means that biotechs can reduce costs and increase trust. It takes away so many of the problems these therapies face as they progress through the clinic to commercial. For example, the ability to alleviate silos in the supply chain while providing an end-to-end solution to track and trace for patients and in near real-time is potentially a game changer for the industry in how quickly and [data integrity] issue free they can accelerate towards patients, commented Tanya Sharma, co-founder of Assurea.

View original post here:
ATMPS and Assurea team up to ensure audit readiness for cell and gene therapy innovators - BioPharma-Reporter.com

Posted in Cell Therapy | Comments Off on ATMPS and Assurea team up to ensure audit readiness for cell and gene therapy innovators – BioPharma-Reporter.com

INmune Bio, Inc. to Participate in January Investor Conferences and a Medical Meeting – Yahoo Finance

Posted: January 5, 2022 at 2:02 am

Boca Raton, Florida, Jan. 04, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the Company), a clinical-stage immunology company focused on developing treatments that harness the patients innate immune system to fight disease, today announced that management will participate in two upcoming investor conferences and a medical meeting. Details of the event are as follows:

LifeSci Advisors 11th Annual Corporate Access EventDavid Moss, Chief Financial Officer, will participate in a panel discussion at the LifeSci Advisors 11th Annual Corporate Access Event. Title: News Voids: How to Keep Investors and Strategics Engaged During Data DesertsDate: Thursday, January 6, 2022Time: 10:00am 10:55am EST

Interested parties may register for the event here.

H.C. Wainwright Bioconnect ConferencePresentation Date: Monday, January 10, 2022Presentation Time: 7:00 AM Eastern Time

Please contact your representative at H.C. Wainwright to schedule a virtual one-on-one meeting.

Allogeneic Cell Therapies Summit Europe (Virtual), Professor Mark Lowdell, PhD, CSO/CMO, InMune Bio, will chair a session at the Allogeneic Cell Therapies Summit Europe (Virtual). Title: Academic to Commercial Development of an Off-the-Shelf Allogeneic ATMP: Three Clinical Trial Case StudiesDate: Wednesday, January 19th, 2022Time: 4:00pm-5:00pm CET / 10:00am-11:00am EST

Dr. Lowdell said, Im so pleased to have been invited to present the background to our first in human trial of INKmune to this specialist group of allogeneic cell therapy developers. INKmune is a unique cellular medicine in having been designed from the very concept as an off-the-shelf and affordable therapy which can be scaled to many thousands of doses. Companies often overlook the real-world challenges of getting cell therapies into hospitals, and we developed our INKmune platform to solve many of the commercialization challenges of cell therapies.

Interested parties may register for the Summit here.

Story continues

About INmune Bio, Inc.

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is in clinical trial to determine if it can treat cancer (INB03), Mild Alzheimers disease, Mild Cognitive Impairment and treatment resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patients NK cells to eliminate minimal residual disease in patients with cancer. INmune Bios product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit http://www.inmunebio.com.

Forward Looking Statements

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03, XPro1595, and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Companys ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Companys business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Companys filings with the Securities and Exchange Commission, including the Companys Annual Report on Form 10-K, the Companys Quarterly Reports on Form 10-Q and the Companys Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact: David Moss, CFO (858) 964-3720DMoss@INmuneBio.com

Investor Contact:Chuck PadalaLifeSci Advisors(646) 627-8390chuck@lifesciadvisors.com

Go here to see the original:
INmune Bio, Inc. to Participate in January Investor Conferences and a Medical Meeting - Yahoo Finance

Posted in Cell Therapy | Comments Off on INmune Bio, Inc. to Participate in January Investor Conferences and a Medical Meeting – Yahoo Finance

FDA Grants Breakthrough Therapy Designation to Patritumab Deruxtecan for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer – Pharmacy Times

Posted: January 5, 2022 at 2:02 am

The Breakthrough Therapy Designation was granted based on data from the dose escalation portion of 2 expansion cohorts of a 3-cohort phase 1 study.

Officials with the FDA have granted Breakthrough Therapy Designation to patritumab deruxtecan (HER2-DXd; Daiichi-Sankyo) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with disease progression on or after treatment with a third generation tyrosine kinase inhibitor and platinum-based therapies.

Patritumab deruxtecan is comprised of a fully human anti-ERBB3 (HER3) immunoglobulin G1 monoclonal antibody attached to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker. It is currently being investigated across multiple cancers as both a monotherapy and in combination with other anticancer treatments.

HER3 is a member of the EGFR family of receptor tyrosine kinases, which are associated with aberrant cell proliferation and survival, according to a press release. Approximately 25% to 30% of lung cancers have an EGFR-activating mutation, including approximately 83% of all NSCLC tumors. Currently, no HER3 directed medicines are approved for the treatment of cancer.

According to the press release, lung cancer is the second most common form of the disease and the leading cause of cancer-related mortality globally, with 80% to 85% of diagnoses classified as NSCLC. Although the efficacy of targeted therapy with EGFR tyrosine kinase inhibitors is well-established in the treatment of advanced EGFR-mutated NSCLC, the development of a broad range of resistance mechanisms commonly leads to disease progression.

After failure of an EGFR tyrosine kinase inhibitor, platinum-based chemotherapy has a limited efficacy with progression-free survival (PFS) of approximately 4.4 to 6.4 months, and subsequent salvage therapies have PFS of between 2.8 and 3.2 months.

The Breakthrough Therapy Designation for patritumab deruxtecan acknowledges the need for new treatment approaches to overcome resistance and improve survival in patients with metastatic [tyrosine kinase inhibitor]-resistant, EGFR-mutated non-small cell lung cancer, said Ken Takeshita, MD, global head of research and development at Daiichi Sankyo, in the press release.

The Breakthrough Therapy Designation for patritumab deruxtecan was granted based on data from the dose escalation portion of 2 expansion cohorts of a 3-cohort phase 1 study. The dose expansion part of the study is evaluating patritumab deruxtecan at 5.6 mg/kg every 3 weeks in 3 cohorts.

Cohort 1 includes patients with locally advanced or metastatic EGFR-mutated NSCLC who experienced disease progression after taking 1 or more EGFR tyrosine kinase inhibitors and 1 or more platinum-based chemotherapy regimens. Cohort 2 includes patients with squamous or non-squamous NSCLC without EGFR-activating mutations following platinum-based chemotherapy and following an anti-programmed death cell 1 (anti-PD-1) or anti-programmed cell death ligand 1 (anti-PD-L-1) antibody regimen. Finally, cohort 3 includes patients with NSCLC with EGFR-activating mutations including any histology other than combined small cell and NSCLC.

The primary objective of the dose expansion part of the study is to assess the efficacy of patritumab deruxtecan as measured by confirmed objective response rate. Secondary endpoints include overall response rate, safety, and pharmacokinetics, according to the press release.

REFERENCE

Patritumab Deruxtecan Granted US FDA Breakthrough Therapy Designation in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer. News release. BusinessWire; December 23, 2021. Accessed January 3, 2021. https://www.businesswire.com/news/home/20211222005517/en

Link:
FDA Grants Breakthrough Therapy Designation to Patritumab Deruxtecan for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer - Pharmacy Times

Posted in Cell Therapy | Comments Off on FDA Grants Breakthrough Therapy Designation to Patritumab Deruxtecan for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer – Pharmacy Times

Addressing the Challenges of AAV Production – Technology Networks

Posted: January 5, 2022 at 2:02 am

Adeno-associated virus (AAV) vectors are a versatile and appealing gene therapy delivery platform, capable of targeting a wide range of cell types. However, AAV must be produced in a living system, and issues with scalability and high production costs have so far limited the widespread adoption of the technology.

Technology Networks spoke to Emily Jackson-Holmes, PhD, associate product manager, Thermo Fisher Scientific, to learn more about the benefits of AAV vectors and reasons for the growing interest in their use. In this interview, Jackson-Holmes also explains how the Gibco AAV-MAX Production System can help to overcome challenges associated with AAV production and ensure regulatory compliance.

Anna MacDonald (AM): Why is there so much interest in AAV vectors? What makes them an ideal option for the delivery of gene therapies?

Emily Jackson-Holmes (EJ): AAV vectors are an attractive and widely pursued option for gene therapy, evidenced by the three approved gene therapies (Luxturna, Zolgensma, and Glybera*) and the many others in development. Specifically, for in vivo delivery of gene therapies, AAV vectors are used for several reasons. Since AAV is non-integrating, it is preferred over lentivirus (LV) for in vivo gene therapy applications, and it also has low immunogenicity. In addition, not only can AAV transduce both dividing and non-dividing cells, but it can target specific cell and tissue types through different naturally occurring and synthetic or hybrid serotypes.

AM: What are some of the main challenges encountered when manufacturing AAV vectors?EJ: Productivity, cost, and scalability have been major challenges in the field. Low productivity is particularly a challenge when considering the amounts of viral vector required for treating diseases with large patient populations. Traditionally, for AAV production in mammalian cells, adhered-based HEK293 systems have been used. These require scaling out in order to scale up the amount of viral vector produced, which in turn requires a large footprint. The suspension adaption of HEK293 cells has enabled implementation of suspension-based production of AAV, which is more amenable to scaling. Finally, another key challenge has been the lack of fit-for-purpose and regulatory-compliant reagents that enable a path to commercialization. Examples of this include the use of cells containing the oncogenic SV40 large T antigen and the use of serum-containing reagents, which both present safety concerns.

AM: Which methods of transfection are most used? What are the advantages of transient transfection?EJ: The most common method of producing AAV is transient transfection of plasmid DNA in HEK293 cells. With helper-free transient transfection specifically, cells are transfected with three plasmids that provide the rep and cap genes, the transgene and the genes that provide the function of a helper virus. The key advantages of using transient transfection are the versatility and speed.

AM: Can you tell us more about the Gibco AAV-MAX Production System and how it can help to address challenges of AAV production?EJ: The AAV-MAX system is a complete suspension-based system for AAV production. The system achieves high AAV titers through high-density suspension culture of a clonal 293F-derived cell line in chemically defined, animal origin free medium. Helper-free triple transfection is performed using a lipid nanoparticle transfection reagent and a novel production enhancer. Each component of the system has been optimized to work together to achieve high titers in a simplified workflow, eliminating the need to optimize reagents and protocols. To enable users of the system to easily scale from research use to clinical and commercial use, the system is designed to scale from shake flasks to bioreactors, and the reagents are fit-for-purpose and regulatory compliant.

AM: The AAV-MAX system reagents are animal origin free. Why is this important?EJ: In the gene therapy space, speed to market is hugely important. A key aspect of this is making sure that AAV production systems initially used at the research stage are chosen with clinical and commercial use in mind, including the choice of reagents that are regulatory friendly. The use of animal origin free reagents reduces the risk of viral contaminants as well as reducing batch-to-batch variability.

AM: What regulatory issues do cell and gene therapy developers face? How does the AAV-MAX Production System address these?EJ: As has been mentioned, the choice of fit-for-purpose and regulatory-friendly reagents ensures a smooth transition to clinical and commercial manufacturing. The AAV-MAX system uses a clonal HEK293 cell line that lacks the T antigen and includes reagents that are all animal origin free. In addition, to complement our currently available research use only (RUO) AAV-MAX system, we will be launching our Gibco Cell Therapy Systems (CTS) version of AAV-MAX next year. Our CTS version provides a documented cell line, GMP-grade reagents, extensive safety testing, and regulatory documentation. Together, these help gene therapy developers to minimize risk and support their regulatory filings.

Emily Jackson-Holmes was speaking to Anna MacDonald, Science Writer for Technology Networks.

*Glybera was approved in 2012 by the European Medicines Agency but was later withdrawn from the market in 2017.

Read more from the original source:
Addressing the Challenges of AAV Production - Technology Networks

Posted in Cell Therapy | Comments Off on Addressing the Challenges of AAV Production – Technology Networks

The Most-Read Myeloma Stories of 2021 – Curetoday.com

Posted: January 5, 2022 at 2:02 am

People with multiple myeloma are living longer than ever, thanks to new treatments and drug combinations that continue to emerge. Alongside these new therapies also come ways to mitigate side effects to ensure that patients live as high-quality life as possible.

From new treatments to noteworthy deaths and clinicians who go the extra mile for their patients, CURE looked back at the most-read myeloma articles of 2021. They were:

1. Treatments for Multiple Myeloma Are Transforming Lives

After receiving a myeloma diagnosis, many patients stress that the disease is incurable. However, new treatments continue to emerge for the disease, and survival times are increasing every few years, explained an expert from The University of Texas MD Anderson Cancer Center.

2. Multiple Myeloma 101: An Incurable But Very Treatable Disease

Dr. Andrew Yee from Massachusetts General Hospital explained the basics of myeloma from symptoms to look out for to staging and common demographics for the disease. He also highlighted recent research and advancements in myeloma that are helping patients with the disease live full lives.

3. Former Defense Secretary Donald Rumsfeld Dies From Multiple Myeloma

In July, Donald H. Rumsfeld, the secretary of defense for Presidents Gerald R. Ford and George W. Bush, died from multiple myeloma. He was 88. In a statement, George W. Bush said that Rumsfeld, never paled before tough decisions and never flinched from responsibility. He brought needed and timely reforms to the Department of Defense, along with a management style that stressed original thinking and accountability.

4. Preventative Kineret May Ease CAR-T Cell Therapy Side Effects in Multiple Myeloma

CAR-T cell therapy is an exciting advance for the treatment of many hematologic malignancies, but can come with severe side effects, such as cytokine release syndrome (CRS). Luckily, recent research found that patients with relapsed/refractory multiple myeloma being treated with the CAR-T cell agent orva-cel had decreased rates of moderate/severe CRS when they took the drug Kineret to prevent it.

5. The Myeloma Nurse Who Climbed a Mountain to Connect With Her Patients

For Donna Catamero, a nurse practitioner who specializes in myeloma, a hike alongside myeloma survivors, loved ones and fellow clinicians was just what she needed as an antidote to the burnout she has been facing in the midst of the COVID-19 pandemic. She climbed Alaskas Kenai Peninsula through Moving Mountains for Multiple Myeloma, a joint effort between CURE and the Multiple Myeloma Research Foundation to raise funds and awareness for the disease.

For the latest news in myeloma, check out CUREs multiple myeloma page.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

See the original post:
The Most-Read Myeloma Stories of 2021 - Curetoday.com

Posted in Cell Therapy | Comments Off on The Most-Read Myeloma Stories of 2021 – Curetoday.com

Stem-cell therapy and platelet-rich plasma in regenerative …

Posted: January 5, 2022 at 2:00 am

J Oral Maxillofac Pathol. 2018 Sep-Dec; 22(3): 367374.

1Department of Oral Pathology, MMNG Halgekar Institute of Dental Science, Belagavi, Karnataka, India

2Center for Incubation, Innovation, Research and Consultancy, Jyothy Institute of Technology, Bengaluru, Karnataka, India

3Department of Oral Pathologist, Chaitanya Dental Clinic, Bengaluru, Karnataka, India

4General and Laparoscopic Surgeon, SSNMC Hospital, Bengaluru, Karnataka, India

1Department of Oral Pathology, MMNG Halgekar Institute of Dental Science, Belagavi, Karnataka, India

2Center for Incubation, Innovation, Research and Consultancy, Jyothy Institute of Technology, Bengaluru, Karnataka, India

3Department of Oral Pathologist, Chaitanya Dental Clinic, Bengaluru, Karnataka, India

4General and Laparoscopic Surgeon, SSNMC Hospital, Bengaluru, Karnataka, India

Received 2018 Sep 3; Accepted 2018 Sep 6.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Regenerative medicine encompasses new emerging branch of medical sciences that involves the functional restoration of tissues or organs caused by severe injuries or chronic diseases. Currently, there are two contending technologies that can repair and restore the damaged tissues, namely platelet-rich plasma (PRP)- and stem cell (SC)-based therapies. PRP is a component of blood that contains platelet concentrations above the normal level and includes platelet-related growth factors and plasma-derived fibrinogen. Platelets are the frontline healing response to injuries as they release growth factors for tissue repair. SCs, on the other hand, are the unspecialized, undifferentiated, immature cells that based on specific stimuli can divide and differentiate into specific type of cells and tissues. Differentiated SCs can divide and replace the worn out or damaged tissues to become tissue- or organ-specific cells with specialized functions. Despite these differences, both approaches rely on rejuvenating the damaged tissue. This review is focused on delineating the preparation procedures, similarities and disparities and advantages and disadvantages of PRP- and SC-based therapies.

Keywords: Platelet-rich plasma, regeneration, stem cells, treatment

Regenerative medicine is a major part of the rapidly emerging biomedical research over the last decade which mainly involves the development of new therapeutic strategies resulting in greater advancement in the field. These recent biomedical approaches have provided the tenacity for medical community to look for alternatives to conventional therapies. Among the several therapeutic strategies available, the use of platelet-rich plasma (PRP) and stem cell (SC) represents the mainstream technologies to repair and rejuvenate the damaged tissue caused due to injury or chronic diseases.[1] PRP is the component of the blood (plasma) which contains five times higher concentrations of platelets above the normal values, i.e., PRP is the volume of autologous plasma that has the platelet concentration above the baseline.[2] Platelets are the tiny components of blood that are rich in growth factors and play a crucial role by forming blood clots during injury. It is a well-known fact that wound healing of damaged tissues depends on the platelet concentrations. PRP acts by nurturing those cells that can heal on their own or can augment the healing process by the resolution of damaged tissues. One of the widely used applications of PRP is in the regeneration and reconstruction of skeletal and connective tissues in the periodontal and maxillofacial diseases and in sports-related injuries.[3,4] Unlike PRP, SCs are the primitive cells that are obtained either from embryos or from the adult tissues. SC has the capacity of self-renewal and can differentiate into as many as 200 different cell types of the adult body.[5] Besides these properties, SC also produces certain growth factors and cytokines that accelerate the healing process at the site of tissue damage. Therapeutic applications of SC include treating many degenerative and inflammatory conditions by replacing the damaged cells in virtually any tissue or organ, where PRP applications serve no benefit.

Although both PRP- and SC-based therapies are destined to perform similar functions in restoring the damaged tissue to function normally, there exists a vast difference in their preparation procedures and their functionality []. SC is isolated from the adult tissues and cultured in sophisticated settings and requires several weeks to grow before they could be used for therapeutics. Contrary to SC, preparation of PRP is simple and involves rapid separation from blood and does not contain SCs for therapeutics per se. Furthermore, compared to SC-based therapies, the curative potential of PRP is considerably lower and regenerative potential is limited to the cells present in such tissues. Due to the similarity in function and the rapid preparations of PRP, several clinicians persuade patients to prefer PRP-based approaches citing that it is similar to SC-based therapies. Considering the existence of such a paradigm between the use of PRP- and SC-based technologies, future research should focus on understanding and clearly defining the molecular mechanism in tissue regeneration. In addition, efficacy and the perseverance of preparative methods, consensus in the preparation methods among different research groups for clinical applications and the significance of such technologies as a substitute for conventional therapies should be delineated and appropriately implemented.[4]

The differences between platelet-rich plasma and stem-cell therapy

The term PRP was introduced in the 1970s to describe the autologous preparations and enrichment of platelets from plasma concentrate.[6] Platelets also known as thrombocytes are produced from megakaryocytes in mammalian bone marrow.[7] They form a first line of cellular defense response following damage to vascular and tissue integrity and play a crucial role in homeostasis, innate immunity, angiogenesis and wound healing.[8,9,10] Under normal conditions, the typical blood samples contain approximately 94% of red blood cells (RBCs), 6% of platelets and 1% of white blood cells. The whole purpose of enriching for PRP is to reverse the RBC-to-platelet ratio to achieve 95% platelets and 5% of RBCs.[11] Enriched fraction of PRP is known to contain high level of growth factors and cytokines that promote tissue regeneration and healing and also reported to be effective in tissue reparative efficacy.[12]

The primary roles of platelets are to form aggregated and also contribute to homeostasis through adhesion, activation and aggregation. Previously, platelets were thought to have only hemostatic activity. However, recent advancement has provided a new perspective on platelet function in regulating inflammation, angiogenesis, SC migration and cell proliferation.[6] Although many studies have supported the beneficial effects of using PRP, the Food and Drug Administration approval for injections of PRP is still under consideration. The only adverse reaction reported is transient pain and localized swelling after injections, but the overall adverse reactions being very low. Further studies are required to assess the efficacy of use of PRP for therapy and its possible long-term adverse reactions.

Platelets play an important role in healing at the site of injury. The increased number of platelets results in increased number of secreted growth factors, thereby increasing the healing process. This phenomenon is attributed as it promotes mitogenesis of healing capable cells and angiogenesis in the tissues. Along with the presence of growth factors, they also contain adhesion molecules that include fibrin, fibronectin and vitronectin which help promote bone formation.[13,14] PRP preparations also play a role in revascularization of damaged tissue by promoting cell migration, proliferation, differentiation and stabilization of endothelial cells in new blood vessels. PRP also restores damaged connective tissue by promoting the migration, proliferation and activation of fibroblasts.[15,16] Platelets also host a vast reservoir of over 800 proteins which when secreted act upon SCs, fibroblasts, osteoblasts and endothelial and epithelial cells.[12] The main purpose of using PRP for therapeutics originated from the idea to deliver the growth factors, cytokines and -granules to the site of injury, which acts as cell cycle regulators, and promote healing process across variety of tissues.[8]

The PRP preparations are known to contain many growth factors, chemokines and cytokines [] which induce the downstream signaling pathways that ultimately lead to synthesis of proteins necessary for collagen, osteoid and extracellular matrix formation.[17] PRP also has numerous cell adhesion molecules including fibrin, fibronectin, vitronectin and thrombospondin that trigger the assimilation of osteoblasts, fibroblasts and epithelial cells. Apart from its role in structural and functional healing, PRP preparations are also been implicated in the reduced use of narcotics, improved sleep and reduction in pain perception.[6,18,19]

The components of platelet-rich plasma and their functions

Preparation of PRP for regeneration of tissues includes three sequential steps blood collection, PRP separation and PRP activation. Briefly, blood is collected using the anticoagulant agent preferably using acid citrate dextrose. The blood is then centrifugation using highly variable protocols with varying time (420 min), velocities (1003000 g), temperature (12C26C) and cycles of centrifugation (1 or 2 cycles). Due to these variable protocols, the platelet concentrations are enriched anywhere between 5 and 9 times. After centrifugation, the blood is separated into three layers the bottom layer (RBCs), middle layer (platelets and white blood cells) and top layer (plasma with gradient of platelet concentrations) [].[11,15]

The procedure of separation of platelet-rich plasma from the venous blood

Considering different parameters and clinical applications, PRP is further classified base on four categories: activated, nonactivated, leukocyte rich and leukocyte poor. Activated PRP is prepared with calcium chloride with or without thrombin, which leads to release of cytokines from the granules in platelets. Nonactivated PRP preparations include platelet contact with intrinsic collagen and thromboplastin, which activate the platelets within connective tissue. In addition, the presence of leukocytes plays a role in inhibiting bacterial growth by improving soft-tissue healing, which would have been hindered by infection.[13] Magalon in 2016 proposed a DEAP classification which is based on dose, efficiency, purity and activation of platelets.[6] Further studies have been carried out to characterize and classify PRP based on preparation (centrifugation and use of anticoagulant), content (platelets, leukocytes and growth factors) and clinical applications. Studies by Dohan Ehrenfest et al. have proposed PRP classifications based on the presence and absence of leukocytes and fibrin architecture.[20]

Pure PRP: Preparations show low-density fibrin network after activation

Leukocyte- and PRP: Preparations contain leukocytes and exhibit low-density fibrin network after activation

Pure platelet-rich fibrin: Preparations lack leukocytes and have high-density fibrin network and exist in activated gel form

Leukocyte- and platelet-rich fibrin: Preparations have leukocytes with high-density fibrin network.

Over the last few years, the use of PRP as a therapeutic tool has made a significant advancement in the field of regenerative medicine particularly in the field of wound healing and skin regeneration, dentistry, cosmetic and plastic surgery, fat grafting, bone regeneration, tendinopathies, ophthalmology, hepatocyte recovery, esthetic surgery, orthopedics, soft-tissue ulcers and skeletal muscle injury and others.[8]

As PRP contains high concentrations of growth factors, it is widely used for hair regrowth. These growth factors promote hair regrowth by binding to their respective receptors expressed by SCs of the hair follicle bulge region and associated tissues.[12]

The application of PRP in dermatology has increased in tissue regeneration, wound healing, scar revision and skin rejuvenating effects. PRP has rich source of growth factors that promote mitogenic, angiogenic and chemotactic properties; it has been used for the treatment of recalcitrant wounds. In cosmetic dermatology, PRP is known to stimulate human dermal fibroblast proliferation and increase type I collagen synthesis. In addition, injections of PRP into deep dermal layers have induced soft-tissue augmentation, activation of fibroblasts, new collagen deposition, new blood vessels and adipose tissue formation. Studies have also shown that PRP along with other techniques has improved the quality of the skin and leads to an increase in collagen and elastic fibers.[6]

PRP has also been used predominantly for musculoskeletal regeneration caused during sports injury. Acute hamstring for injuries accounts for approximately 29% of all sports-related injuries where PRP-based treatments have shown beneficial effects. Patellar tendinopathy also known as jumper's knee is the most common cause of anterior knee pain among athletes. Application of PRP is known to promote repair and reduce inflammation.[6] Achilles tendinopathy is another sports injury associated with severe pain and swelling at the tendinous insertion site. The rupture might get worse without proper treatment. Currently, muscle-strengthening exercise and anti-inflammatory medications are the only treatment options. The use of PRP was proposed as a treatment option.[13]

Osteoarthritis is one of the most common knee disorders which are commonly seen in elderly people due to cartilage damage and inflammatory changes. Several meta-analysis conducted on the these patients using both leukocyte-rich and leukocyte-poor PRP has displayed the benefits in favor of using PRP for osteoarthritis. PRP is known to stimulate chondrocytes and synoviocytes to produce cartilage matrix. In rotator cuff tear, which is the most common cause of shoulder disability, the inclusion of PRP-based therapy has beneficial effects for tendinous injuries. However, further clinical trials and metadata analysis are required for the clinical use of PRP as effective treatment technologies.[13] Apart from these diseases, PRP has also known to suppress the growth of particular species of bacteria such as Staphylococcus aureus.[21] It is also shown to improve endometrial thickness in patients undergoing in vitro fertilization treatment.[22]

In conclusion, there is an increase in the evidence that shows the beneficial use of platelet-based applications in tissue regeneration. However, there is considerable debate on the effectiveness of platelet-based applications, especially between human- and animal-based studies which could be due to the methodological differences among different research groups. There is a tremendous possibility for exploration in regenerative medicine which could use PRP for potential therapeutic applications.

The major advantage of the use of PRP for therapeutic applications is the immediate preparation of PRP, which does not require any preservative facilities. PRP is considered safe and natural as the preparation involves using own cells without any further modifications. This also ensures that the preparations do not elicit immune response. Since the preparations are from the same person, the chances of getting the bloodborne contaminations are minimized. As a large number of populations succumb to musculoskeletal injuries or disorders, application of PRP-based therapies has shown promising results.[11,23]

The use of PRP as such does not have major demerits. However, under certain circumstances, PRP applications can result in injection-site morbidity, infection or injury to nerves or blood vessels. Scar tissue formation and calcification at the injection site have also been reported. Some patients have also experienced acute ache or soreness at the site of injection and also in the muscle or deeper areas such as the bone. Patients with compromised immune system or with predisposed diseases are more susceptible to infection at the injured area. Studies have reported allergic reactions among few individuals who have taken PRP-enriched fractions. Since PRP is given intravenously, the chances of damaging the artery or veins which could result in blood clot exist. Studies have also advised against using PRP-based therapies among individuals with a history of heavy smoking and drug and alcohol use and patients diagnosed with platelet dysfunction syndromes, thrombocytopenia, hyperfibrinogenemia, hemodynamic instability, sepsis, acute and chronic infections, chronic liver disease, anticoagulation therapy, chronic skin diseases or cancer and metabolic and systemic disorders due to the complications associated with the PRP-based treatment.[11]

Recent advancement in the SC research has emphasized on the use of adult SC (ASC)-based therapies, which were not cured by conventional medicines. Tissue-resident adult progenitor SCs have clinical importance due to their potential cell sources for transplantation in regenerative medicine and cancer therapies. The ability for indefinite self-renewal and multilineage differentiation into other types of cells represents SCs, which offers great promise in replacing the nonfunctional or lost cells to regenerate damaged or diseased tissues.[24] The use of small subpopulation of adult stem or progenitor cells from tissues or organs from the same individual provides the possibility of stimulating those in vivo differentiation or cell replacement and gene therapies with multiple applications in humans without the risk of graft rejection. Research on tissue-resident SCs has explored the clinical interest in cell replacement-based therapies in regenerative medicine and cancer therapies.[25]

Based on their origin, SCs are divided into two types embryonic SCs (ESCs) and ASCs. ESCs are derived from epiblast of the blastocyst from which many tissues of embryo arise, whereas ASCs are localized in adult organs [] where these cells function to replace damaged cells during tissue regeneration.[26,27] SCs are further classified into four types based on their transdifferentiation potential which include totipotent, pluripotent, multipotent and unipotent SC.[24] ESCs are known to have totipotent and pluripotent in nature and have the ability to differentiate into cells of three germ layers endoderm, mesoderm and ectoderm.[28] ASC is multipotent and can give rise to differentiated cells of anyone germ layer.[29] Unipotent SCs arise from multipotent cells and are dedicated to differentiate into specific type of tissue, for example, precursors for cardiomyocytes present in human heart or satellite cells characteristic for skeletal muscles are dedicated to differentiate into specific tissue.[30]

Source and Type of cells produced from a normal adult stem cells

The use of SCs for therapeutic purposes was proposed as early in the 1960s because of their inherent ability to differentiate into multiple cell lines.[17] This requires careful isolation and culturing which has to be done in aseptic condition. SCs are extracted either from bone marrow or fat tissue and are sometimes used in conjunction with platelets. Once isolated, SCs can retain their ability to transform into a variety of cell types. So far, there is no standardized procedure to isolate and to characterize SCs; however, specific markers are available to identify them.[31] Mesenchymal SCs (MSCs) are extensively studied cell types in regenerative medicine due to their immunomodulatory properties.[32] Studies have shown that MSC has the capacity to differentiate into osteocytes, adipocytes, myocytes and cells of chondrogenic lineage.[17] MSCs express markers that include CD73, CD90 and CD105 (endoglin) but not CD11b, CD14, CD19, CD34, CD45, CD79a and human leukocyte antigen Class II.[33] Hematopoietic SCs express two important hematopoietic markers, i.e., CD45 and CD34.[34] Certain markers have been used as pluripotent markers such as OCT4, NANOG and SOX2. OCT4 is a transcriptional factor involved in early embryogenesis and very much essential for maintenance of pluripotency of SCs.[35] NANOG is a transcription factor and is involved in self-renewal capacity of undifferentiated SCs and has the ability to form any cell type of three germ layers of human body.[36,37] The third pluripotency gene is sex-determining region SOX2 which is also a transcription factor and maintains self-renew capacity of undifferentiated SCs.[38]

Although the use of SC has immense medical benefits, their applications in many diseases are still in the research and clinical trial phase and further studies are required for its long-term use in clinical settings. SCs have much more potent regulatory role in immune system. Compared to PRP-based approach, SC therapy can be very promising in treatment of many degenerative diseases where PRP is not suitable. SCs are also been used to treat many dental-related disorders such as regeneration and reconstruction of dental and oromaxillofacial tissues.[39,40] MSCs have shown to support blood and lymphangiogenesis and also shown to act as precursors of endothelial cells and pericytes and promote angiogenesis.[41] MSCs are known to orchestrate wound repair by cellular differentiation, immune modulation and production of growth factors that drive neovascularization and re-epithelialization [].

The promise of stem-cell therapy in regenerative medicine

SC-based therapies are emerging as a powerful tool for treating many degenerative and inflammatory diseases. Apart from differentiating into new tissue that is lost, they also coordinate in repair response. SC can be isolated from patients and can be amenable to autologous transplantation. Treatment with single isolation can provide lifetime repository of cells for the patients. Furthermore, SC can be genetically modified to overexpress crucial genes that can augment wound healing and decrease the formation of scars.[42]

Although SC has added advantage over PRP-based approach in regenerating the damaged tissue, there are certain concerns in using SC for therapies. SC propensity toward self-renewal and differentiation is highly influenced by their local environment making it difficult to interpret how a population of culture expands MSC may behave in vivo. Isolation and characterization of SC are crucial and even the isolated SC may have low survival rates. Culturing of SC without contamination requires highly experienced personnel and sophisticated laboratory settings. The chances of microbial contamination of SC might result in complications, especially in those patients whose immune system is compromised. Careful monitoring and observation of this cell-based therapy are of paramount importance, since evidence has shown that adipose-derived MSCs have lost genetic stability over time and were prone to tumor formation.[43] Based on the specific application, SC should be differentiated into appropriate cell types before they can be clinically used, failure of which may have deleterious effects. Furthermore, SC-based therapies require regular follow-up to monitor regenerated tissue over a period of complete recovery of a patient. In vivo niches, SCs are present under hypoxic conditions and change in oxygen levels can induce oxidative stress, which can influence SC phenotype, proliferation, fate, pluripotency, etc., Therefore, in vitro culture conditions used to study MSCs should be maintained similar to their in vivo niches.[44]

PRP and SC therapy is continuously studied for their regenerative benefit in wound healing, sports medicine and chronic pain treatment. Although their preparation, mechanism and action and efficacy have been shown to be different, studies have shown that both PRP and SC can complement each other and might have an added advantage when used in combination. For example, PRP offers a suitable microenvironment for MSCs to promote proliferation and differentiation and accelerates wound healing capabilities. Conversely, PRP can be a powerful tool to attract cell populations, such as MSCs, a combination of which provides a promising approach for the treatment.[45] Some of the common injuries that are treated using combinational therapy include tendonitis, rotator cuff tears, osteoarthritis, spine conditions, arthritic joints, overuse injuries, inflammation from herniated disc and others.[46,47]

Despite many beneficial effects of PRP in treating clinical conditions and with minimal side effects, the use of PRP as a regenerative medicine is still in its infancy. The major constraint is the limited availability of adequate controlled clinical trials and lack of consensus related to PRP preparation techniques. Nevertheless, the use of PRP-based preparations has shown promising results in some clinical settings, especially in the field of dermatology, dentistry, ophthalmology, orthopedics and others. Future research has to be focused on understanding the molecular mechanisms involved in the PRP-based therapies in tissue regeneration and long-term side effects associated with the use of PRP. Optimum concentration required to attain maximum tissue regeneration response without eliciting the immune response has to be determined. Investigating these key questions would increase the use of PRP-based regenerative medicines in treating acute and chronic ailments rather than using conventional therapies which would include surgeries followed by prolonged supportive therapies.

Although PRP and SC represent a promising treatment for many diseases, large-scale clinical trials using both in vitro and in vivo studies are required to establish the true effectiveness of the treatments. SC-based therapies have shown promising results in clinical settings, and further work should be carried out to optimize the transplantation procedures that ensure functional integration, proliferation, differentiation and migration of transplanted tissue-specific ASCs to repair and replace the damaged tissue and their long-term survival in the tissue niche.

In conclusion, PRP-based therapeutic option could be used as an alternative form of therapy alone or in combination with other conventional treatments. In this regard, it is important to understand the formulations and specific enrichment fractions that could be suitable for particular treatment. Furthermore, research has to focus on standardizing the PRP formulations and have a consensus data from the clinical trials from different research groups for better prognosis and to use as an alternative to conventional therapies.

Nil.

There are no conflicts of interest.

See original here:
Stem-cell therapy and platelet-rich plasma in regenerative ...

Posted in Regenerative Medicine | Comments Off on Stem-cell therapy and platelet-rich plasma in regenerative …

Regenerative Medicine Monmouth County NJ

Posted: January 5, 2022 at 2:00 am

Meet Dr. Daniel Savarino, DO, RMSK

Dr. Daniel Savarino, DO is a sport and regenerative medicine specialist in Tinton Falls, NJ.

Dr.Savarino, an established and highly skilled physician, has over 10 years of experience in Sports Medicine. He obtained his medical degree at the New York College of Osteopathic Medicine and completed a Family Practice Residency at North Shore LIJ Hospital at Plainview, where he served as Chief Resident in 2007-2008. Before starting Apex Center for Regenerative Medicine, Dr. Savarino worked in one of the busiest orthopedic and sports medicine practices in New York City, where he had extensive training in Musculoskeletal Ultrasound and Ultrasound Guided Injections.Dr. Savarino performs procedures a few other physicians in the country perform, and people travel from different parts of America and from different countries to be treated by him!

Dr. Savarino has demonstrated cutting-edge knowledge and skills needed to provide top care to his patients in the area of Regenerative Medicine, Sports Medicine, and Pain Management. In addition to helping patients avoidunneededsurgery, Dr Savarino has received hundreds of hours of additional training in Non -Surgical Aesthetics & Body Contouring, Age Management Medicine and Bioidentical HormoneReplacement .

Originally posted here:
Regenerative Medicine Monmouth County NJ

Posted in Regenerative Medicine | Comments Off on Regenerative Medicine Monmouth County NJ

Regenerative Medicine | CRISPR

Posted: January 5, 2022 at 2:00 am

Combining CRISPR and stem cells to treat diabetes

Decades of clinical data with islet transplants indicate that beta-cell replacement approaches may offer curative benefit to patients with insulin-requiring diabetes. ViaCyte has pioneered the approach of generating pancreatic-lineage cells from stem cells and delivering them safely and efficiently to patients. PEC-Direct, ViaCytes lead product candidate currently being evaluated in the clinic, uses a non-immunoprotective delivery device that permits direct vascularization of the cell therapy. This approach has the potential to deliver durable benefit; however, because the patients immune system will identify these cells as foreign, PEC-Direct will require long-term immunosuppression to avoid rejection. As a result, PEC-Direct is being developed as a therapy for the subset of patients with type 1 diabetes at high risk for complications.

Our gene-editing technology offers the potential to protect the transplanted cells from the patients immune system by ex vivo editing immune-modulatory genes within the stem cell line used to produce the pancreatic-lineage cells. The speed, specificity and multiplexing efficiency of CRISPR/Cas9 make our technology ideally suited to this task. We have established significant expertise in immune-evasive gene editing through our allogeneic CAR-T programs. The combination of ViaCytes stem cell capabilities and our gene-editing capabilities has the potential to enable a beta-cell replacement product that may deliver durable benefit to patients without triggering an immune reaction.

Visit link:
Regenerative Medicine | CRISPR

Posted in Regenerative Medicine | Comments Off on Regenerative Medicine | CRISPR

Global Regenerative Medicine Market is Expected to Reach …

Posted: January 5, 2022 at 2:00 am

DUBLIN, December 22, 2021--(BUSINESS WIRE)--The "Global Regenerative Medicine Market Size, Share & Trends Analysis Report by Product (Cell-based Immunotherapies, Gene Therapies), by Therapeutic Category (Cardiovascular, Oncology), and Segment Forecasts, 2021-2027" report has been added to ResearchAndMarkets.com's offering.

The global regenerative medicine market size is expected to reach USD 57.08 billion by 2027, growing at a CAGR of 11.27% over the forecast period.

Recent advancements in biological therapies have resulted in a gradual shift in preference toward personalized medicinal strategies over the conventional treatment approach. This has resulted in rising R&D activities in the regenerative medicine arena for the development of novel regenerative therapies.

Furthermore, advancements in cell biology, genomics research, and gene-editing technology are anticipated to fuel the growth of the industry. Stem cell-based regenerative therapies are in clinical trials, which may help restore damaged specialized cells in many serious and fatal diseases, such as cancer, Alzheimer's, neurodegenerative diseases, and spinal cord injuries.

For instance, various research institutes have adopted Human Embryonic Stem Cells (hESCs) to develop a treatment for Age-related Macular Degeneration (AMD).

Constant advancements in molecular medicines have led to the development of gene-based therapy, which utilizes targeted delivery of DNA as a medicine to fight against various disorders.

Gene therapy developments are high in oncology due to the rising prevalence and genetically driven pathophysiology of cancer. The steady commercial success of gene therapies is expected to accelerate the growth of the global market over the forecast period.

Regenerative Medicine Market Report Highlights

The number of companies engaged in the development of advanced therapies is continuously increasing over the past few years. This is anticipated to increase the competition among companies to create a specific and efficient pipeline

The therapeutics segment dominated the market in 2020 due to the high usage of primary cell-based therapies along with advances in stem cell and progenitor cell therapies. The implementation of these therapies in dermatological, musculoskeletal, and dental application results in the highest share of this segment

Stem cell and progenitor cell-based therapies are anticipated to witness rapid growth due to high investments in this research space and an increasing number of stem cell banks

With the rise in R&D and clinical trials of regenerative medicines, key players are offering several consulting services leading to lucrative growth of the services segment

The oncology segment is estimated to account for the largest revenue share by 2027 owing to the high prevalence of cancer indications, which drives the demand for better solutions. The presence of a strong pipeline of regenerative medicines for cancer treatment also supplements the segment growth

North America dominated the market in 2020 and is projected to continue its dominance over the forecast period. A significant number of universities and research organizations investigating various stem cell-based approaches for regenerative apposition in the U.S. propels the region's growth

Asia Pacific is projected to witness the fastest CAGR over the forecast period due to the emergence of key players and rapid adoption of cell-based approaches in the healthcare

Key Topics Covered:

Story continues

Market Variables, Trends, & Scope

Market Driver Analysis

Presence of a strong pipeline and a large number of clinical trials

High economic impact of regenerative medicine

Emerging applications of gene therapy in regenerative medicine

Increasing government & private funding to support the development of regenerative medicine

Technological advancements in regenerative medicine (stem cell, tissue engineering, and nanotechnology)

Increase in strategic partnerships to accelerate development & commercialization of regenerative medicines

Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to rise in demand for regenerative treatments

Market Restraint Analysis

High cost of treatment

Regulatory issues pertaining to stem cells, tissues engineering, and regenerative medicines

Market Challenge Analysis

Current challenges of on-market gene therapies

Penetration & Growth Prospect Mapping for Therapeutic Category, 2020

Reimbursement Framework

Reimbursement Framework & Clinical Translation of RM

Reimbursement Framework for RM: Europe

Reimbursement Framework for RM: South Korea

Technology Overview

Autologous Cell Transplantation

Next-Generation Cell-Based Therapies

CAR-T Cell Technologies

Cost Structure Analysis

User Perspective Analysis

Market Influencer Analysis

Consumer Behavior Analysis

Regenerative Medicine Market - SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)

Industry Analysis - Porter's

Regenerative Medicine Market Analysis Tools

Major Deals & Strategic Alliances Analysis

Merger & Acquisition Deals

Collaboration & Partnerships

Business Expansion

Market Entry Strategies

Pharmaceutical and biotechnology companies

Raw material supplier

Contract Service Provider

Distributor

Companion Diagnostics companies:

Case Studies

MACI (Vericel Corporation):

LAVIV (Azficel-T) (Fibrocell Technologies):

Competitive Analysis

Covid-19 Impact Analysis

COVID-19 Impact Analysis

Challenges Analysis

Manufacturing & Supply Challenges

Opportunities analysis

Need For Development Of New Therapies Against SARS-COV-2

T-cell Therapy

Cell Therapy

Gene Therapy

Tissue engineering

Rise In Demand For Supply Chain Management Solutions

Challenges in Manufacturing T-cell Therapies Against COVID-19

Clinical Trial Analysis

Regenerative Medicine Market: Product Business Analysis

Regenerative Medicine Market: Therapeutic Category Business Analysis

Regenerative Medicine Market: Regional Business Analysis

Companies Mentioned

Integra Lifesciences Corporation

Astellas Pharma Inc.

Cook Biotech, Inc.

Bayer AG

Astrazeneca plc

F. Hoffmann-La Roche Ltd.

Pfizer, Inc.

Merck Kgaa

Abbott

Vericel Corporation

Novartis AG

GlaxoSmithKline plc.

Baxter International Inc.

Boehringer Ingelheim GmbH

Amgen Inc.

Cesca Therapeutics Inc. / Thermogenesis Holdings Inc.

U.S Stem Cell, Inc.

Bristol-Myers Squibb Company

Eli Lilly and Company

Nuvasive, Inc.

Organogenesis, Inc.

Mimedx Group, Inc.

More here:
Global Regenerative Medicine Market is Expected to Reach ...

Posted in Regenerative Medicine | Comments Off on Global Regenerative Medicine Market is Expected to Reach …

Where regenerative medicine and orthobiologics fit in …

Posted: January 5, 2022 at 2:00 am

Treatment providers know that some injuries and illnesses remain unresolved even after multiple forms of mitigation are attempted. Much to the patients dismay, they simply may be unable to find relief through chiropractic care, physical therapy, electrical stimulation, nutrition balance and many other forms of treatment. The effects of car accidents, for example, can cause a lifetimes worth of neck and back numbness, tingling and headaches. At this point, it is time to pose the option of regenerative medicine and orthobiologics to alleviate symptoms and help the body heal from within.1

Regenerative interventional orthopedics is an emerging field, which includes the injections of orthobiologics (such as bone-marrow concentrate and platelet-rich plasma). Commonly, it is used to enhance strength, improve mobility, treat injuries and mitigate chronic conditions.

Often, when people think of regenerative medicine, stem cells come to mind. However, many forms of this treatment pre-date stem cell research. Previously-introduced methods have become more commonplace over the years.

Here are several types available today, some of which are commonplace in a musculoskeletal-based regenerative medicine practice:

As evident, there are many different types of regenerative medicine, and the applications are vast in regard to its benefits and ways in which chiropractors can integrate with this form of treatment. Furthermore, regenerative therapy and research show no signs of slowing. The benefits can mean the difference between a life of pain and one of recovery.

Some benefits of regenerative medicine that have been shown in the literature include:3

These are all tremendous benefits that extend beyond palliative care and are viable options for a chiropractor to consider working with or referring out for.

While the requirements to administer regenerative medicine treatment are typically beyond the training and scope of practice of most chiropractors, there is a perfect relationship between regenerative medicine and chiropractic care. Chiropractors have the ability to refer out to a medical provider who performs regenerative medicine as well as employ providers depending on the state in which they are located and licensed.

It is important to remember and confirm with the state board in which a chiropractor is licensed regarding the scope of practice in that state and any laws or statutes regarding administering, referring, managing or hiring a provider who performs regenerative medicine. Limiting the risk of injury to patients by adhering to the laws and statutes is an important part of the patient experience and will keep your practice legal and compliant.

Additionally, clinics that often provide regenerative medicine and orthobiologics use MRIs, ultrasounds and fluoroscopy before delivering any injections, which is another step in the process to consider when arranging any regenerative medicine services in your clinic.

In addition to continually defining emerging standards, it is important that chiropractors cooperate with different health professionals when treating a variety of musculoskeletal conditions. When chiropractors partner with regenerative medicine doctors, they are able to provide a number of additional patient benefits including enhanced medical opinions regarding diagnosis and treatment as well as providing more services for the patient. This is incredibly helpful as each provider has a similar goal in mind.

Regenerative medicine parallels chiropractic medicine because both aim to treat root causes of a patients conditions.1 Regenerative medicine does this by replacing lost cells or organs, whereas chiropractic does so via manipulation and alignment of the body.

While some chiropractors work solo or with other chiropractors, they are increasingly integrating with other health professionals to offer a more comprehensive treatment for pain and other musculoskeletal conditions. This integration can be achieved by working together in a multi-specialty or multidisciplinary spine clinic.6

The goal and scope of regenerative medicine physicians and chiropractors are complementary. Both fields aim to change the way things are done in a non-pharmacological and non-surgical manner by:

Regenerative medicines are used to replenish, strengthen and heal tissues, muscles and tendons. They also help treat injured, weakened and compromised joints. The chiropractic profession has intentionally sought to circumvent the use of non-narcotic and non-surgical care in favor of a system that improves the bodys ability to heal itself. This makes sense given chiropractors focus on anatomy and the self-healing capabilities of the body.

Furthermore, regenerative medicine and orthobiologics have great potential to treat several health conditions outside the scope of treatment for a chiropractor but well suited for a referral such as diabetes, heart diseases, and emphysema.

The aim of chiropractors and regenerative medicine physicians are similar. Both aim to treat conditions without surgical or pharmacological intervention.

Here is an example of how a chiropractor and regenerative medicine professional can work together: Say, for instance, a patient has a neck injury that has caused a measurable degree of instability in the cervical or lumbar spine. Intervention will be used to re-establish the patients comfort and range of motion. However, knowing that the tissues in the neck are damaged, the chiropractor and regenerative medicine specialist decide to take a collaborative approach by creating a plan that includes information from the MRI, examination, and patient history.

The chiropractor will conduct the manipulation of the spine and the regenerative medicine specialist will direct injections to the small ligaments and tissues that are generally damaged in injured spines. These processes complement each other and increase the patients long-term outcomes.

As patient care continues to evolve and patients seek additional treatment options, there are numerous ways for regenerative medicine and orthobiologics to begin integrating with chiropractic offices. Begin your search by meeting with your local regenerative medicine or pain management practitioners and discussing a collaboration as the integrative model of care is on the rise.

ANTHONY CRIFASE, DC, CNS, DACBN, LDN, is the director of professional relations of DocShop Pro. He is double board-certified in clinical nutrition and maintains an active chiropractic practice in Denver, Colo. With experience in multiple different industries and as a seasoned chiropractor who understands the ins and outs of practice management, he is on a mission to help other practitioners maximize their time, revenue and systems. Learn more at docshoppro.com.

The rest is here:
Where regenerative medicine and orthobiologics fit in ...

Posted in Regenerative Medicine | Comments Off on Where regenerative medicine and orthobiologics fit in …

Page 552«..1020..551552553554..560570..»